A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis.

Plevy, Scott

A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. [electronic resource] - Gastroenterology Nov 2007 - 1414-22 p. digital

Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

1528-0012

10.1053/j.gastro.2007.08.035 doi


Adolescent
Adult
Aged
Antibodies, Monoclonal--adverse effects
Antibodies, Monoclonal, Humanized
CD3 Complex--immunology
CD4-Positive T-Lymphocytes--pathology
CD8-Positive T-Lymphocytes--pathology
Colitis, Ulcerative--drug therapy
Dose-Response Relationship, Drug
Endoscopy, Gastrointestinal
Female
Humans
Male
Middle Aged
Severity of Illness Index